Oral Lefamulin vs Moxifloxacin for Early Clinical Response among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial -

Oral Lefamulin vs Moxifloxacin for Early Clinical Response among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Infection and infectious diseases | Respiratory disorders
Summary
RCT (n=738) found that among patients with community-acquired bacterial pneumonia (CABP), 5-day oral lefamulin was non-inferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose; 90.8% vs. 90.8% respectively.
UKMi comment

A related editorial discusses the need for new anti-bacterials to treat CABP because of growing antibacterial resistance and safety concerns with standard care.

Lefamulin is a pleuromutilin antibiotic, which interferes with bacterial protein synthesis via a specific interaction with the 23S rRNA of the 50S bacterial ribosome subunit.

The US FDA approved lefamulin (Xenleta) to treat adults with CAPB in August 2019. The developmental status in the EU is currently unknown.
Related links: Editorial